Published in Obesity and Diabetes Week, November 5th, 2007
The poster presentation of preclinical data shows that MSI-1436 demonstrated selective inhibition of PTP-1B but did not inhibit the activities of DDP-IV, TC-PTP or SHP-2 nor inhibit ligand binding to the CB1 or 5HT2C receptors. Additional in vitro testing demonstrated that MSI-1436 does not activate PPAR (alpha, beta/delta or gamma) nor bind to 250 different kinases. In an animal model, MSI-1436 was found to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week